State Street Corp Purchases 82,665 Shares of Selecta Biosciences Inc (SELB)

State Street Corp increased its position in Selecta Biosciences Inc (NASDAQ:SELB) by 118.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 152,430 shares of the company’s stock after purchasing an additional 82,665 shares during the period. State Street Corp’s holdings in Selecta Biosciences were worth $3,027,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of SELB. Nationwide Fund Advisors boosted its holdings in Selecta Biosciences by 224.5% in the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after acquiring an additional 4,561 shares in the last quarter. Rhumbline Advisers bought a new stake in Selecta Biosciences in the second quarter worth $239,000. New York State Common Retirement Fund boosted its holdings in Selecta Biosciences by 184.0% in the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after acquiring an additional 8,099 shares in the last quarter. Trexquant Investment LP bought a new stake in Selecta Biosciences in the second quarter worth $334,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Selecta Biosciences in the second quarter worth $392,000. 54.44% of the stock is currently owned by institutional investors.

Selecta Biosciences Inc (SELB) opened at $10.06 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48. Selecta Biosciences Inc has a 1-year low of $8.70 and a 1-year high of $24.02.

Several research firms have commented on SELB. Zacks Investment Research raised Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Saturday, November 11th. UBS downgraded Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price target on shares of Selecta Biosciences in a report on Tuesday, November 7th. Finally, ValuEngine downgraded Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $23.50.

In other Selecta Biosciences news, Director Amir Nashat sold 42,610 shares of the stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $20.03, for a total value of $853,478.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Werner Cautreels bought 20,000 shares of the stock in a transaction on Monday, November 13th. The stock was purchased at an average cost of $9.31 per share, for a total transaction of $186,200.00. Following the acquisition, the insider now owns 321,203 shares of the company’s stock, valued at approximately $2,990,399.93. The disclosure for this purchase can be found here. In the last three months, insiders acquired 90,098 shares of company stock worth $843,933 and sold 355,658 shares worth $6,955,732. 41.90% of the stock is currently owned by corporate insiders.

WARNING: “State Street Corp Purchases 82,665 Shares of Selecta Biosciences Inc (SELB)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/12/11/state-street-corp-purchases-82665-shares-of-selecta-biosciences-inc-selb.html.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Institutional Ownership by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply